What's new

What's new

Human medicines European public assessment report (EPAR): Gilenya, fingolimod, Date of authorisation: 17/03/2011, Revision: 38, Status: Authorised

Human medicines European public assessment report (EPAR): Gilenya, fingolimod, Date of authorisation: 17/03/2011, Revision: 38, Status: Authorised

19 December 2024

Cyanokit

Cyanokit

19 December 2024

Veterinary medicines European public assessment report (EPAR): Nobivac L4, Vaccine to prevent Leptospira infections in dogs, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Nobivac L4, Vaccine to prevent Leptospira infections in dogs, Status: Authorised

19 December 2024

Veterinary medicines European public assessment report (EPAR): Versican Plus DHPPi, canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Versican Plus DHPPi, canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus, Status: Authorised

19 December 2024

Veterinary medicines European public assessment report (EPAR): Versican Plus DHPPi/L4, live, attenuated Canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus inactivated, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Versican Plus DHPPi/L4, live, attenuated Canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus inactivated, Status: Authorised

19 December 2024

Trametinib product-specific bioequivalence guideline

Trametinib product-specific bioequivalence guideline

19 December 2024

Human medicines European public assessment report (EPAR): Idelvion, albutrepenonacog alfa, Date of authorisation: 11/05/2016, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Idelvion, albutrepenonacog alfa, Date of authorisation: 11/05/2016, Revision: 13, Status: Authorised

19 December 2024

Human medicines European public assessment report (EPAR): Axitinib Accord, axitinib, Date of authorisation: 19/09/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Axitinib Accord, axitinib, Date of authorisation: 19/09/2024, Revision: 1, Status: Authorised

19 December 2024

Human medicines European public assessment report (EPAR): Carbaglu, carglumic acid, Date of authorisation: 24/01/2003, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Carbaglu, carglumic acid, Date of authorisation: 24/01/2003, Revision: 20, Status: Authorised

19 December 2024

Human medicines European public assessment report (EPAR): Vocabria, cabotegravir, Date of authorisation: 17/12/2020, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Vocabria, cabotegravir, Date of authorisation: 17/12/2020, Revision: 11, Status: Authorised

19 December 2024